4 research outputs found
ΠΠ°ΡΡΠΈΠΊΡΠΈΠ½Ρ 2, 7 ΠΈ 9 ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ: Π²ΡΡΡΠ½Π΅Π½ΠΈΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠΉ ΡΠ²ΡΠ·ΠΈ Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠ΅ΠΉ Π±Π΅Π»ΠΊΠ° HER-2/neu
The comparative analysis of the quantity of matrix metalloproteinases (MMP) 2,7 and 9 in breast cancer is carried out; the concentration of sex hormones receptors and protein HER-2/neu are determined. Authentically high values MMP-2 and MMP-7 are found in a tumor tissue in contrast to the normal one. The elevated concentration of ΠΠΠ -2 in a tumor is connected with receptor status (p < 0,05). The highest values of concentration ΠΠΠ -7 and ΠΠP- 9 are found at RE-, RP- and HER-2/neu + tumors, and also in the tumors with the size more than 4,0 cm.ΠΡΠΎΠ²Π΅Π΄Π΅Π½ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π· (ΠΠΠ) 2,7 ΠΈ 9 Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΡΠΊΠ°Π½ΡΡ
ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΎ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠΎΠ² ΠΏΠΎΠ»ΠΎΠ²ΡΡ
Π³ΠΎΡΠΌΠΎΠ½ΠΎΠ², Π±Π΅Π»ΠΊΠ° her-2/neu. ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠΎΠΊΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠΠ-2 ΠΈ -7 ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Π² ΡΠΊΠ°Π½ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΠΎΠΉ ΡΠΊΠ°Π½ΡΡ. ΠΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ ΠΠΠ 2 Π² ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΡΠ²ΡΠ·Π°Π½ΠΎ Ρ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ½ΡΠΌ ΡΡΠ°ΡΡΡΠΎΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (p < 0,05). ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ ΠΠΠ -7 ΠΈ ΠΠΠ -9 ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΠΏΡΠΈ Π Π-, Π Π- ΠΈ HER-2/neu+ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
, Π° ΡΠ°ΠΊΠΆΠ΅ Π² Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΡ
ΡΠ°Π·ΠΌΠ΅ΡΠΎΠΌ Π±ΠΎΠ»Π΅Π΅ 4,0 ΡΠΌ
Matrix metalloproteinases 2, 7, and 9 in tumors and sera of patients with breast cancer
Enzyme immunoassay showed that the content of matrix metalloproteinases (MMP) 2 and 7 in tumors was higher than in the adjacent histologically intact tissue in 91 and 76% patients with breast cancer, respectively, while MMP-9 levels in the tumor and intact tissue were virtually the same. Serum concentrations of MMP-2 and MMP-7 did not correlate with their levels in the tumors, were within the normal range, and virtually did not decrease after removal of the primary tumor. Serum levels of MMP-9 in patients were significantly lower than in the control and increased after surgery in 85% patients. No clear-cut relationship between the studied parameters and clinical morphological prognostic factors of breast cancer was detected. Β© 2011 Springer Science+Business Media, Inc
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ ΡΠΎΡΡΠ΄ΠΎΠ², ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΠΏΠΎΠ΄ΠΎΠ±Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ°Β 1 ΠΈΒ ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΠΎΠΉ ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Ρ 7 Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΈΒ ΠΎΠΏΡΡ ΠΎΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²
Aim: To perform aΒ comparative analysis with simultaneous measurement of vascular endothelial growth factor (VEGF), insulin-like growth factorΒ 1 (IGF1) and matrix metalloproteinaseΒ 7 (MMP7) in serum samples taken from healthy women and ovarian cancer patients; to perform association of these markers with their expression in primary tumors depending on clinical, morphological and biochemical characteristics of the disease and its prognosis. Materials and methods: We assessed 54Β treatment-naΓ―ve patients with ovarian cancer aged fromΒ 23 to 74Β years (meanβΒ±βSD, 53.2βΒ±β1.9), being at various FIGO stages of the disease. The control group consisted of 120Β healthy women of matched age and reproductive status, in whom serum biomarker levels were studied. Patient survival was assessed by the Kaplan-Meier method, with survival curves compared with log-rank test. All analyses were done with βSTATISTICAβ and SPSS software. Results: Serum VEGF levels in ovarian cancer patients were significantly (pββ0.0001) higher compared those in the control. The most informative cut-off values differentiating the groups studied were serum VEGF values of β350Β pg/ml (median value in the control) and β505Β pg/ml (upper quartile in the control). With 505Β pg/ml taken as aΒ threshold, the test had sensitivity of 79.6% and specificity of 75%. Another cut-off value of serum VEGF level between the patients with ovarian cancer and the control group (510Β pg/ml) was derived from ROC curves and 75%Β sensitivity and 78.2%Β specificity. No acceptable cut-off value for serum IGF1 to differentiate between the patients with ovarian cancer and the controls could be obtained from the ROC curves. Serum MMP7 levels in the patients with ovarian cancer were significantly higher than those in the control group (Mann-Whitney test pββ0.0001). With ROC curves, the best sensitivity to specificity ratio for MMP7 value of 4.6Β ng/ml was obtained to differentiate between the patients with ovarian cancer and the controls (sensitivity 83.3%, and specificity 81%). The variance analysis did not reveal any association between serum VEGF, IGF1 and MMP7 and age of patients with ovarian cancer, tumor histology, concomitant somatic and gynecological diseases, and CA-125 levels. Serum VEGF and IGF1 levels did not correlate with the stage of ovarian cancer, in contrast to MMP7, whose levels were significantly higher in stages IIIcβIV. The median VEGF level significantly increased as the degree of differentiation decreased from 510 to 622Β pg/ml (pββ0.002), while median IGF1, on the contrary, decreased fromΒ 219 to 116Β pg/ml (pββ0.0001). There was aΒ direct correlation between serum and tumor VEGF levels in ovarian cancer patients (rβ=β0.65, pββ0.0001). On the contrary, there was an inverse correlation between serum and tumor IGF1 levels (rβ=β-0.68, pββ0.0001). Serum and tumor MMP7 levels remained unrelated to each other. Tumor VEGF, IGF1 and MMP7 content was unrelated to the age of the patients, their reproductive status, presence of concomitant somatic and gynecological diseases, histology of ovarian cancer, and serum CA-125Β levels. VEGF levels in the tumor were not associated with the stage of ovarian cancer, but in patients with initial stages Ia and Ib stages MMP7 values significantly lower (2.1Β ng/mg protein) compared to those in stages IIIc and IV (6.1 and 4.7Β ng/mg protein, respectively, pββ0.05). Similar pattern was noted for IGF1: tumor IGF1 values in the patients with stagesΒ IaβIb were significantly lower (0.5Β ng/mg protein) than those with stages IIIcβIV (median, 1.3β1.4Β ng/mg protein). AΒ significant increase in both serum and tumor VEGF levels was detected in the patients with ovarian cancer with decreased degree of differentiation. On the contrary, tumor IGF1 levels, but not serum ones, were significantly increased from 0.6 to 1.4Β ng/ml in the patients with poorly differentiated ovarian cancer. MMP7 tumor expression did not depend on the degree of its differentiation. Serum VEGF levels above 700Β pg/ml and tumor levels of above 590Β ng/mg protein should be considered as unfavorable prognostic factors in patients with ovarian cancer.Π¦Π΅Π»ΡΒ β ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° ΡΠ½Π΄ΠΎΡΠ΅Π»ΠΈΡ ΡΠΎΡΡΠ΄ΠΎΠ² (VEGF), ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΠΏΠΎΠ΄ΠΎΠ±Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° 1-Π³ΠΎΒ ΡΠΈΠΏΠ° (ΠΠ€Π -1) ΠΈΒ ΠΌΠ°ΡΡΠΈΠΊΡΠ½ΠΎΠΉ ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Π°Π·Ρ 7-Π³ΠΎΒ ΡΠΈΠΏΠ° (ΠΠΠ-7) Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΠΆΠ΅Π½ΡΠΈΠ½ ΠΈΒ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ²ΡΠ·Ρ ΡΡΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΡΒ ΠΈΡ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ Π²Β ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
ΡΒ ΡΡΠ΅ΡΠΎΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
, ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΒ Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈΒ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈΒ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ 54Β Π½Π΅Π»Π΅ΡΠ΅Π½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π²Β Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡΒ 23 Π΄ΠΎΒ 74Β Π»Π΅Ρ (ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 53,2βΒ±β1,9Β Π³ΠΎΠ΄Π°) Π²Β ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ°Π΄ΠΈΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° (ΠΏΠΎ FIGO). ΠΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 120Β Π·Π΄ΠΎΡΠΎΠ²ΡΡ
ΠΆΠ΅Π½ΡΠΈΠ½ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° ΠΈΒ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ°, ΡΒ ΠΊΠΎΡΠΎΡΡΡ
ΠΈΠ·ΡΡΠ°Π»ΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ. ΠΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΠ°ΠΏΠ»Π°Π½Π°Β β ΠΠ΅ΠΉΠ΅ΡΠ°, ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΠΊΡΠΈΠ²ΡΡ
Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΡΠ°ΡΡΡΠΈΡΡΠ²Π°Π»ΠΈ ΡΒ ΠΏΠΎΠΌΠΎΡΡΡ Log-Rank test. ΠΡΠ΅ Π²ΡΡΠΈΡΠ»Π΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π° ΠΏΠ΅ΡΡΠΎΠ½Π°Π»ΡΠ½ΠΎΠΌ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ΅ ΡΒ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠ°ΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΠΊΠ΅ΡΠΎΠ² STATISTICA ΠΈΒ SPSS. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΠΎΠ²Π½ΠΈ VEGF Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π±ΡΠ»ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ (Ρββ0,0001) Π²ΡΡΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΒ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΠΌΠΈ ΡΡΠΎΠ²Π½ΡΠΌΠΈ, ΡΠ°Π·Π΄Π΅Π»ΡΡΡΠΈΠΌΠΈ ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΠ΅ Π³ΡΡΠΏΠΏΡ, Π±ΡΠ»ΠΈ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ VEGF ΠΌΠ΅Π½Π΅Π΅ 350Β ΠΏΠ³/ΠΌΠ» (ΠΌΠ΅Π΄ΠΈΠ°Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ Π²Β ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅) ΠΈΒ Π±ΠΎΠ»Π΅Π΅ 505Β ΠΏΠ³/ΠΌΠ» (Π²Π΅ΡΡ
Π½ΡΡ ΠΊΠ²Π°ΡΡΠΈΠ»Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ Π²Β ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅). Π§ΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΡΠ΅ΡΡΠ° ΠΏΠΎ ΠΏΠΎΡΠΎΠ³Ρ 505Β ΠΏΠ³/ΠΌΠ» ΡΠ°Π²Π½ΡΠ»Π°ΡΡ 79,6%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ 75%. ΠΡΠ΅ ΠΎΠ΄Π½ΠΈΠΌ ΡΠ°Π·Π΄Π΅Π»ΡΡΡΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ VEGF Π²Β Π³ΡΡΠΏΠΏΠ°Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² ΠΈΒ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π±ΡΠ»ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΠ°, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΠΎΠ΅ ΡΒ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
ROC ΠΈΒ ΡΠ°Π²Π½ΠΎΠ΅ 510Β ΠΏΠ³/ΠΌΠ», Π΅Π³ΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ: ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ 75%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ 78,2%. ΠΡΠΈΠ΅ΠΌΠ»Π΅ΠΌΠΎΠ³ΠΎ ΡΠ°Π·Π΄Π΅Π»ΡΡΡΠ΅Π³ΠΎ ΡΡΠΎΠ²Π½Ρ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠ€Π -1 Π²Β Π³ΡΡΠΏΠΏΠ°Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² ΠΈΒ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΒ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
ROC, Π½Π΅ Π½Π°ΠΉΠ΄Π΅Π½ΠΎ. Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΠΠΠ-7 Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² Π±ΡΠ»ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ (ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π°Β β Π£ΠΈΡΠ½ΠΈ, Ρββ0,0001) Π²ΡΡΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΒ ΠΊΠΎΠ½ΡΡΠΎΠ»Π΅ΠΌ. Π‘Β ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
ROC ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ Π½Π°ΠΈΠ»ΡΡΡΠ΅Π΅ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΈΒ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠ°Π·Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π³ΡΡΠΏΠΏ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² ΠΈΒ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΏΠΎ ΡΡΠΎΠ²Π½Ρ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΠΠ-7, ΡΠ°Π²Π½ΠΎΠ³ΠΎ 4,6Β Π½Π³/ΠΌΠ» (ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ 83,3%, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ 81%). ΠΠΈΡΠΏΠ΅ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π½Π΅ Π²ΡΡΠ²ΠΈΠ» ΡΠ²ΡΠ·ΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ VEGF, ΠΠ€Π -1 ΠΈΒ ΠΠΠ-7 ΡΒ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΡΡΠΎΠ΅Π½ΠΈΠ΅ΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, ΡΒ ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠΈΠΌΠΈ ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈΒ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, ΡΒ ΡΡΠΎΠ²Π½ΡΠΌΠΈ Π‘Π-125. ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ VEGF ΠΈΒ ΠΠ€Π -1 Π½Π΅ ΠΎΡΡΠ°ΠΆΠ°Π»ΠΈ ΡΡΠ°Π΄ΠΈΡ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², Π²Β ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΠΠΠ-7, ΡΡΠΎΠ²Π½ΠΈ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ Π±ΡΠ»ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅ ΠΏΡΠΈ IIIcβIV ΡΡΠ°Π΄ΠΈΡΡ
. ΠΠ΅Π΄ΠΈΠ°Π½Π° VEGF ΠΏΠΎΠ²ΡΡΠ°Π»Π°ΡΡ ΠΏΠΎ ΠΌΠ΅ΡΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΡΒ 510 Π΄ΠΎ 622Β ΠΏΠ³/ΠΌΠ» (Ρββ0,002), Π°Β ΠΠ€Π -1, Π½Π°ΠΎΠ±ΠΎΡΠΎΡ, ΡΠ½ΠΈΠΆΠ°Π»Π°ΡΡ ΡΒ 219Β Π΄ΠΎ 116Β ΠΏΠ³/ΠΌΠ» (Ρββ0,0001). ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΠΏΡΡΠΌΠ°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ VEGF Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΈΒ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² (rβ=β0,65; pββ0,0001). ΠΠ»Ρ ΠΠ€Π -1, Π½Π°ΠΏΡΠΎΡΠΈΠ², ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΠΎΠ±ΡΠ°ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠ° Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΈΒ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
(rβ=β-0,68; pββ0,0001). Π£ΡΠΎΠ²Π½ΠΈ ΠΠΠ-7 Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΈΒ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π΅ Π±ΡΠ»ΠΈ ΡΠ²ΡΠ·Π°Π½Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ±ΠΎΠΉ. Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ VEGF, ΠΠ€Π -1 ΠΈΒ ΠΠΠ-7 Π²Β ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π΅ Π±ΡΠ»ΠΎ ΡΠ²ΡΠ·Π°Π½ΠΎ ΡΒ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ, ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΡΠΌ ΡΡΠ°ΡΡΡΠΎΠΌ, Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠΈΡ
ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΒ Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΡΡΠΎΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², ΡΡΠΎΠ²Π½ΡΠΌΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ Π‘Π-125. Π£ΡΠΎΠ²Π½ΠΈ VEGF Π²Β ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π΅ Π±ΡΠ»ΠΈ ΡΠ²ΡΠ·Π°Π½Ρ ΡΠΎ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ², ΠΎΠ΄Π½Π°ΠΊΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ Π½ΠΈΠ·ΠΊΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠΠ-7 ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΡΒ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΒ Π½Π°ΡΠ°Π»ΡΠ½ΡΠΌΠΈ Ia ΠΈΒ Ib ΡΡΠ°Π΄ΠΈΡΠΌΠΈ (2,1Β Π½Π³/ΠΌΠ³ Π±Π΅Π»ΠΊΠ°) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΒ IIIc ΠΈΒ IV ΡΡΠ°Π΄ΠΈΡΠΌΠΈ (6,1 ΠΈΒ 4,7Β Π½Π³/ΠΌΠ³ Π±Π΅Π»ΠΊΠ° ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; Ρββ0,05). ΠΠΎΠ΄ΠΎΠ±Π½Π°Ρ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΡΡΡ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΠΈΒ Π΄Π»Ρ ΠΠ€Π -1: ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ Π½ΠΈΠ·ΠΊΠΈΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠ€Π -1 Π²Β ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΒ IaβIbΒ ΡΡΠ°Π΄ΠΈΡΠΌΠΈ (0,5Β Π½Π³/ΠΌΠ³ Π±Π΅Π»ΠΊΠ°) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΒ IIIcβIVΒ ΡΡΠ°Π΄ΠΈΡΠΌΠΈ (ΠΌΠ΅Π΄ΠΈΠ°Π½Π° 1,3β1,4Β Π½Π³/ΠΌΠ³ Π±Π΅Π»ΠΊΠ°). ΠΡΡΠ²Π»Π΅Π½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ VEGF ΠΊΠ°ΠΊ Π²Β ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ, ΡΠ°ΠΊ ΠΈΒ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ² ΠΏΡΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ. Π£ΡΠΎΠ²Π½ΠΈ ΠΠ€Π -1 Π²Β ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, Π²Β ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ, ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΏΠΎΠ²ΡΡΠ°Π»ΠΈΡΡ ΡΒ 0,6 Π΄ΠΎ 1,4Β Π½Π³/ΠΌΠ» ΡΒ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΡΒ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΡΠ°ΠΊΠ° ΡΠΈΡΠ½ΠΈΠΊΠΎΠ². ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΠΠ-7 Π²Β ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π΅ Π·Π°Π²ΠΈΡΠ΅Π»ΠΈ ΠΎΡ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΅Π΅ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ. Π£ΡΠΎΠ²Π½ΠΈ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ VEGF Π±ΠΎΠ»Π΅Π΅ 700Β ΠΏΠ³/ΠΌΠ», Π°Β Π² ΡΠΊΠ°Π½ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π±ΠΎΠ»Π΅Π΅ 590Β Π½Π³/ΠΌΠ³ Π±Π΅Π»ΠΊΠ° ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΡΠΈΡΠ°ΡΡ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΒ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΡΠΈΡΠ½ΠΈΠΊΠΎΠ²
Matrix metalloproteinases 2, 7, and 9 in tumors and sera of patients with breast cancer
Enzyme immunoassay showed that the content of matrix metalloproteinases (MMP) 2 and 7 in tumors was higher than in the adjacent histologically intact tissue in 91 and 76% patients with breast cancer, respectively, while MMP-9 levels in the tumor and intact tissue were virtually the same. Serum concentrations of MMP-2 and MMP-7 did not correlate with their levels in the tumors, were within the normal range, and virtually did not decrease after removal of the primary tumor. Serum levels of MMP-9 in patients were significantly lower than in the control and increased after surgery in 85% patients. No clear-cut relationship between the studied parameters and clinical morphological prognostic factors of breast cancer was detected. Β© 2011 Springer Science+Business Media, Inc